Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.
- DOI
- 10.1186/s13058-026-02313-9
- Published
- 2026 May 29
- Container
- Breast cancer research : BCR
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13058-026-02313-9,
title = {Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.},
author = {Ishikawa T and Uemura Y and Seki H and Kitada M and Saito T and Yamada K and Takao S and Takabatake D and Yokota T and Kitahara M and Kikawa Y and Yamada A and Toh U and Nishimura H and Kaise H and Yamagami K and Nishimura R and Taira N and Narui K and Mukai H},
year = {2026},
journal = {Breast cancer research : BCR},
doi = {10.1186/s13058-026-02313-9},
url = {https://doi.org/10.1186/s13058-026-02313-9}
}RIS
TY - JOUR TI - Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study. AU - Ishikawa T AU - Uemura Y AU - Seki H AU - Kitada M AU - Saito T AU - Yamada K AU - Takao S AU - Takabatake D AU - Yokota T AU - Kitahara M AU - Kikawa Y AU - Yamada A AU - Toh U AU - Nishimura H AU - Kaise H AU - Yamagami K AU - Nishimura R AU - Taira N AU - Narui K AU - Mukai H PY - 2026 JO - Breast cancer research : BCR DO - 10.1186/s13058-026-02313-9 UR - https://doi.org/10.1186/s13058-026-02313-9 ER -
APA
T, I., Y, U., H, S., M, K., T, S., K, Y., S, T., D, T., T, Y., M, K., Y, K., A, Y., U, T., H, N., H, K., K, Y., R, N., N, T., K, N., & H, M. (2026). Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.. Breast cancer research : BCR. https://doi.org/10.1186/s13058-026-02313-9
Source records
- pubmed · retrieved 2026-09-26T04:47:59.981Z